Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Navarro

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Seminars in Arthritis and Rheumatism|November 15, 2024
The cause is worse than the effect: Inequities in the United States health system; how could we change them?Iris Navarro-Millán
BMC Rheumatology|March 20, 2019
Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatmentAprajita Jagpal, Iris Navarro-Millán
Current Opinion in Rheumatology|January 4, 2021
Racial, ethnic, and healthcare disparities in rheumatoid arthritisKevin Yip, Iris Navarro-Millán
Current Opinion in Rheumatology|March 21, 2013
Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisIris Navarro-Millán, Jeffrey R Curtis
Arthritis & Rheumatology (Hoboken, N.J.)|September 20, 2020
ReplyIris Navarro-Millán, Mary K Crow
Rheumatology (Oxford, England)|December 25, 2019
Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis: replyIris Navarro-Millán, Parag Goyal, Monika M Safford
Rheumatology (Oxford, England)|October 2, 2018
Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritisIris Navarro-Millán, Parag Goyal, Monika M Safford
Current Opinion in Rheumatology|August 16, 2021
The role of immunomodulatory medications in the treatment of COVID-19Sebastian E Sattui, Mary K Crow, Iris Navarro-Millán
Clinical Therapeutics|March 27, 2012
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptorIris Navarro-Millán, Jasvinder A Singh, Jeffrey R Curtis
Clinical Therapeutics|October 26, 2013
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritisIris Navarro-Millán, Sebastian E Sattui, Jeffrey R Curtis
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Seminars in Arthritis and Rheumatism|November 15, 2024
The cause is worse than the effect: Inequities in the United States health system; how could we change them?Iris Navarro-Millán
BMC Rheumatology|March 20, 2019
Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatmentAprajita Jagpal, Iris Navarro-Millán
Current Opinion in Rheumatology|January 4, 2021
Racial, ethnic, and healthcare disparities in rheumatoid arthritisKevin Yip, Iris Navarro-Millán
Current Opinion in Rheumatology|March 21, 2013
Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisIris Navarro-Millán, Jeffrey R Curtis
Arthritis & Rheumatology (Hoboken, N.J.)|September 20, 2020
ReplyIris Navarro-Millán, Mary K Crow
Rheumatology (Oxford, England)|December 25, 2019
Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis: replyIris Navarro-Millán, Parag Goyal, Monika M Safford
Rheumatology (Oxford, England)|October 2, 2018
Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritisIris Navarro-Millán, Parag Goyal, Monika M Safford
Current Opinion in Rheumatology|August 16, 2021
The role of immunomodulatory medications in the treatment of COVID-19Sebastian E Sattui, Mary K Crow, Iris Navarro-Millán
Clinical Therapeutics|March 27, 2012
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptorIris Navarro-Millán, Jasvinder A Singh, Jeffrey R Curtis
Clinical Therapeutics|October 26, 2013
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritisIris Navarro-Millán, Sebastian E Sattui, Jeffrey R Curtis
Pageof 8